Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment

被引:7
|
作者
Yu, Hongjie [1 ]
Shi, Zhuqing [1 ]
Lin, Xiaoling [2 ]
Bao, Quanwa [3 ]
Jia, Haifei [2 ]
Wei, Jun [1 ]
Helfand, Brian T. [1 ]
Zheng, Siqun. L. [1 ]
Duggan, David [4 ]
Lu, Daru [3 ]
Mo, Zengnan [5 ]
Xu, Jianfeng [1 ,2 ]
机构
[1] NorthShore Univ HealthSyst, Program Personalized Canc Care, 1001 Univ Pl, Evanston, IL 60201 USA
[2] Fudan Univ, Huashan Hosp, Fudan Inst Urol, Shanghai, Peoples R China
[3] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[4] City Hope Natl Med Ctr, Translat Genom Res Inst, Phoenix, AZ USA
[5] Guangxi Med Univ, Ctr Genom & Personalized Med, Nanning, Guangxi Zhuang, Peoples R China
关键词
clinical validity; genetic risk score; prostate cancer; GENOME-WIDE ASSOCIATION; MEN; PREDICTION; VARIANTS; BIOPSY;
D O I
10.1002/pros.23920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several polygenic risk score (PRS) methods are available for measuring the cumulative effect of multiple risk-associated single nucleotide polymorphisms (SNPs). Their performance in predicting risk at the individual level has not been well studied. Methods We compared the performance of three PRS methods for prostate cancer risk assessment in a clinical trial cohort, including genetic risk score (GRS), pruning and thresholding (P + T), and linkage disequilibrium prediction (LDpred). Performance was evaluated for score deciles (broad-sense validity) and score values (narrow-sense validity). Results A training process was required to identify the best P + T model (397 SNPs) and LDpred model (3 011 362 SNPs). In contrast, GRS was directly calculated based on 110 established risk-associated SNPs. For broad-sense validity in the testing population, higher deciles were significantly associated with higher observed risk;P(trend)was 7.40 x 10(-11), 7.64 x 10(-13), and 7.51 x 10(-10)for GRS, P + T, and LDpred, respectively. For narrow-sense validity, the calibration slope (1 is best) was 1.03, 0.77, and 0.87, and mean bias score (0 is best) was 0.09, 0.21, and 0.10 for GRS, P + T, and LDpred, respectively. Conclusions The performance of GRS was better than P + T and LDpred. Fewer and well-established SNPs of GRS also make it more feasible and interpretable for genetic testing at the individual level.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 50 条
  • [1] Systematic evaluation of narrow-sense validity of polygenic risk score for prostate cancer in a Chinese prostate biopsy cohort
    Wu, Yishuo
    Ruan, Xiaohao
    Gao, Peng
    Da, Huang
    Fang, Zujun
    Xu, Danfeng
    Jiang, Haowen
    Ding, Qiang
    Lin, Xiaoling
    Lu, Daru
    Na, Rong
    CLINICAL GENETICS, 2023, 103 (06) : 636 - 643
  • [2] Concept and benchmarks for assessing narrow-sense validity of genetic risk score values
    Yu, Hongjie
    Shi, Zhuqing
    Wu, Yishuo
    Wang, Chi-Hsiung
    Lin, Xiaoling
    Perschon, Chelsea
    Isaacs, William B.
    Helfand, Brian T.
    Zheng, S. Lilly
    Duggan, David
    Mo, Zengnan
    Lu, Daru
    Xu, Jianfeng
    PROSTATE, 2019, 79 (10) : 1099 - 1105
  • [3] Polygenic Risk Scores in Prostate Cancer Risk Assessment and Screening
    Byrne, Lindsey
    Toland, Amanda Ewart
    UROLOGIC CLINICS OF NORTH AMERICA, 2021, 48 (03) : 387 - 399
  • [4] Validation of a prostate cancer polygenic risk score
    Black, Mary H.
    Li, Shuwei
    LaDuca, Holly
    Lo, Min-Tzu
    Chen, Jefferey
    Hoiness, Robert
    Gutierrez, Stephanie
    Tippin-Davis, Brigette
    Lu, Hsiao-Mei
    Gielzak, Marta
    Wiley, Kathleen
    Shi, Zhuqing
    Wei, Jun
    Zheng, Siqun Lilly
    Helfand, Brian T.
    Isaacs, William
    Xu, Jianfeng
    PROSTATE, 2020, 80 (15) : 1314 - 1321
  • [5] Polygenic risk score in prostate cancer
    Oh, Jong Jin
    Hong, Sung Kyu
    CURRENT OPINION IN UROLOGY, 2022, 32 (05) : 466 - 471
  • [6] Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review
    Song, Sang Hun
    Byun, Seok-Soo
    INVESTIGATIVE AND CLINICAL UROLOGY, 2021, 62 (03) : 256 - 266
  • [7] Clinical features of prostate cancer by polygenic risk score
    Spears, Christina
    Xu, Menglin
    Shoben, Abigail
    Dason, Shawn
    Toland, Amanda Ewart
    Byrne, Lindsey
    FAMILIAL CANCER, 2024, 23 (04) : 499 - 505
  • [8] Prostate cancer risk prediction using a polygenic risk score
    Sipeky, Csilla
    Talala, Kirsi M.
    Tammela, Teuvo L. J.
    Taari, Kimmo
    Auvinen, Anssi
    Schleutker, Johanna
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [9] Prostate cancer polygenic risk score and prediction of lethal prostate cancer
    Klein, Robert J.
    Vertosick, Emily
    Sjoberg, Dan
    Ulmert, David
    Ronn, Ann-Charlotte
    Haggstrom, Christel
    Thysell, Elin
    Hallmans, Goran
    Dahlin, Anders
    Stattin, Par
    Melander, Olle
    Vickers, Andrew
    Lilja, Hans
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [10] Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk
    Darst, Burcu F.
    Sheng, Xin
    Eeles, Rosalind A.
    Kote-Jarai, Zsofia
    Conti, David V.
    Haiman, Christopher A.
    EUROPEAN UROLOGY, 2021, 80 (02) : 134 - 138